69 3.3.2. Continual technical improvement of product, ., p.76 ,
77 4.1.1. In pre-marketing, p.78 ,
EC on the Community code relating to medicinal products for human use, 2001. ,
About Drug Development, p.9, 2012. ,
Drug Discovery, 2012. ,
Presentation and format of the dossier Common Technical Document (CTD), 2006. ,
Small Business Assistance: Frequently Asked Questions for New Drug Product Exclusivity, www.fda.gov/Drugs/DevelopmentApproval Process/SmallBusinessAssistance/ucm069962.htm, 2012. ,
How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nature Reviews Drug Discovery, vol.116, 2010. ,
DOI : 10.1038/nrd3078
The Cost of New Drug Discovery and Development, Discovery Medicine ,
Association des professionnels du générique, GEMME) http://www.medicamentsgeneriques.info/son-marche/lemarche-mondial-et-europeen, 2012. ,
The Product Life Cycle of Engineered Metals: A Comparative Analysis of the Application of Product Life Cycle Theory, Journal of Business & Industrial Marketing, vol.7, issue.2, 1992. ,
DOI : 10.1108/08858629210037173
Competitive strategies for new product marketing over the life cycle, Manage. Sci, 1965. ,
Modeling sustainable product life cycle decision support systems, Int. J. Prod. Econ, 2009. ,
DOI : 10.1016/j.ijpe.2009.06.011
Stage of the Product Life Cycle, Business Strategy, and Business Performance., Academy of Management Journal, vol.27, issue.1, 1984. ,
DOI : 10.2307/255954
The Product Life Cycle: Analysis and Applications Issues, Journal of Marketing, vol.45, issue.4, 1981. ,
DOI : 10.2307/1251472
Principles and practice of Marketing, 2006. ,
Market Share Strategy and the Product Life Cycle, Business Strategy, and Business Performance, J. Marketing, 1974. ,
Production Lifecycle Management, 21 st Century Paradigm for Product Realization, 2004. ,
Toward a Contingency Theory of Business Strategy, Acad. Manage. J, 1975. ,
DOI : 10.1007/978-3-662-41484-2_7
The brand loyalty life cycle: Implications for marketers, Journal of Brand Management, vol.12, issue.4, 2005. ,
DOI : 10.1057/palgrave.bm.2540221
étude clinique : besoin identifié mais les patients ciblés sont localisés dans des pays émergents où il n'y a pas de centre de recherche ; besoin mais pour lequel il est nécessaire de screener un nombre « infini ,
hors LCM) : développement des formes galéniques et des dispositifs de haute technicité à valeur ajoutée (dispositif de haute technicité : utilisés pour les produits du diabète) => le but étant d'étendre l'usage du produit dans le temps ,